Catalent Pharma Solutions has made three appointments. Paul Wituschek, formerly of Penn Pharmaceutical Services, has joined as vice president (VP) of sales for the development and clinical Services business unit.
Former Biogen Idec employee Sven Lee has been hired as VP of business development to lead the biologics team. Finally, Paul Ingram joins from Bilcare Global Clinical Supplies to fill the newly created role of European sales director for clinical supply services.
Doug Young has joined Publicis Touchpoint Solutions, an outsourced message delivery business, as VP of the clinical centre-of-excellence. Young worked at Bristol-Myers Squibb for 16 years and also led a research team at Sandoz.
Novella Clinical has named Richard Farris as senior director for project management. Farris last worked as chief operations officer at Health Decisions. Novella has also promoted Michael Doyle, formerly of OSI Pharmaceuticals, to global head of regulatory affairs.
And finally, former PPD CEO Fred Eshelman is to remain at the company in some capacity. in the short-term at least. Eshelman is due to retake the role of CEO on an interim basis in May.
“We hear he’s not retiring”, said Dave Windley, managing director, healthcare equity research at Jeffries & Company. “That's not to say that he is reassuming the CEO title, but he is clearly haunting the offices of anyone so bold as to authorise discretionary spending.”